A Universal Multiplex Assay System for High-Throughput Clinical Applications
A Universal Multiplex Assay System for High-Throughput Clinical Applications
批准号:
7852428
负责人:
Wei-Jun Qian
金额:
$213.87万
依托单位国家:
美国
项目类别:
财政年份:
2009
资助国家:
美国
项目状态:
已结题
起止时间:
2009-09-30 至 2014-06-30
关键词:
AntibodiesAreaBiological AssayBiological MarkersBiomedical ResearchClinicalCoupledDetectionDevelopmentEnzyme-Linked Immunosorbent AssayFutureGasesGenomicsGoalsHealthcareIonsMass Spectrum AnalysisMeasurementMedicalMonitorPhaseProteomicsReagentSamplingSignal TransductionSourceSpecificitySpectrometryStagingSystemTechnologyValidationabstractingbasecandidate validationclinical applicationclinical practicecommercializationdisease diagnosishuman diseaseimprovedinstrumentinterestion mobilityionizationmass spectrometermetabolomicsnano-electrospraynoveloutcome forecastpressureprotein metabolitepublic health relevancetool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (Provided by the applicant)
Abstract: Recent advances in genomics, proteomics, and metabolomics make the "omics" technologies powerful discovery-based tools for identifying candidate biomarkers for human diseases; however, it has not been successful so far to establish new biomarkers for clinical practice by utilizing these technologies. The main bottleneck lies in the lack of effective tools for high-throughput validation. To overcome this bottleneck I propose to develop a novel "reagent-free" mass spectrometry-based universal multiplex assay system that will provide high throughput quantitative measurements for hundreds of low-abundance protein and metabolite analytes, independent of antibody-based reagents. The goal for this technology platform is to achieve a profound advance over current MS-platforms by providing >1000-fold enhancement in analyte signal intensities, sufficient for detecting low-abundance species, and >5000-fold improvement in resolving power for extremely high specificity detection. These advances will be achieved by developing and integrating 1) a novel subambient pressure ionization source with nanoelectrospray array, 2) advanced ion-funnel interfaces, 3) novel multi-stage gas-phase ion mobility technology (differential mobility analyzer coupled to field asymmetric ion mobility spectrometry) for separating and selecting analytes of interest, and (4) a new triple-stage pentaquardrupole (QqQqQ) mass spectrometer for further isolating as well as detecting ions. The optimized platform will have a potential analytical throughput of >100 samples per day, sensitivity for broadly analyzing low-abundance candidate biomarkers without enrichment, and the multiplexing power to monitor up to 1000 analytes simultaneously. At least 3-4 orders of magnitude enhancement in sensitivity or detection dynamic range (i.e., to a level comparable or superior to current ELISA) is anticipated, a significant advance over current assay platforms. Such a novel assay system is a disruptive technology that will revolutionize many areas of biomedical research, current medical practice, and the future of health care, as well as the biomedical research field in general through instrument commercialization.
Public Health Relevance: The objective of this project is to develop a novel mass spectrometry-based universal multiplex assay system for high throughput clinical discovery and validations of candidate biomarkers of human diseases. The development will have major clinical and translational impact on current biomedical research by accelerating biomarker discovery and implementation in clinical practices. Large number of candidate biomarkers for various human diseases can be effectively screened for validation using the new assay system to discover markers for improved disease diagnosis, prognosis, and treatment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Robust Mass Spectrometric Protein/Peptide Assays for Type 1 Diabetes Clinical Applications
-
批准号:10730900
-
项目类别:
-
资助金额:$98.26万
-
财政年份:2023
-
负责人:Wei-Jun Qian
-
依托单位:
Coordination Core
-
批准号:10259782
-
项目类别:
-
资助金额:$10.84万
-
财政年份:2020
-
负责人:Wei-Jun Qian
-
依托单位:
Coordination Core
-
批准号:10685584
-
项目类别:
-
资助金额:$11.24万
-
财政年份:2020
-
负责人:Wei-Jun Qian
-
依托单位:
Coordination Core
-
批准号:10118875
-
项目类别:
-
资助金额:$10.84万
-
财政年份:2020
-
负责人:Wei-Jun Qian
-
依托单位:
Reverse Sensitivity Analysis for Identifying Predictive Proteomics Signatures of Cancer
-
批准号:10395957
-
项目类别:
-
资助金额:$57.38万
-
财政年份:2019
-
负责人:Wei-Jun Qian
-
依托单位:
Multiplex Mass Spectrometric Protein Assays for Precise Monitoring of the Pathophysiology of Obesity
-
批准号:9918021
-
项目类别:
-
资助金额:$101.03万
-
财政年份:2019
-
负责人:Wei-Jun Qian
-
依托单位:
Reverse Sensitivity Analysis for Identifying Predictive Proteomics Signatures of Cancer
-
批准号:9923630
-
项目类别:
-
资助金额:$71.57万
-
财政年份:2019
-
负责人:Wei-Jun Qian
-
依托单位:
Multiplex Mass Spectrometric Protein Assays for Precise Monitoring of the Pathophysiology of Obesity
-
批准号:10238054
-
项目类别:
-
资助金额:$75.28万
-
财政年份:2019
-
负责人:Wei-Jun Qian
-
依托单位:
Multiplex Mass Spectrometric Protein Assays for Precise Monitoring of the Pathophysiology of Obesity
-
批准号:10448306
-
项目类别:
-
资助金额:$74.39万
-
财政年份:2019
-
负责人:Wei-Jun Qian
-
依托单位:
Multiplex Mass Spectrometric Protein Assays for Precise Monitoring of the Pathophysiology of Obesity
-
批准号:10020391
-
项目类别:
-
资助金额:$75.56万
-
财政年份:2019
-
负责人:Wei-Jun Qian
-
依托单位:
Reverse Sensitivity Analysis for Identifying Predictive Proteomics Signatures of Cancer
-
批准号:10615630
-
项目类别:
-
资助金额:$56.41万
-
财政年份:2019
-
负责人:Wei-Jun Qian
-
依托单位:
Serum protein biomarkers for predicting type 1 diabetes
-
批准号:9180023
-
项目类别:
-
资助金额:$179.52万
-
财政年份:2016
-
负责人:Wei-Jun Qian
-
依托单位:
国内基金
海外基金
层出镰刀菌氮代谢调控因子AreA 介导伏马菌素 FB1 生物合成的作用机理
-
批准号:2021JJ40433
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2021
-
负责人:孙磊
-
依托单位:
寄主诱导梢腐病菌AreA和CYP51基因沉默增强甘蔗抗病性机制解析
-
批准号:32001603
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:段真珍
-
依托单位:
AREA国际经济模型的移植.改进和应用
-
批准号:18870435
-
项目类别:面上项目
-
资助金额:2.0万元
-
批准年份:1988
-
负责人:史树中
-
依托单位: